drugset / Trial / NCT04140461
AmB Dose for Cryptococcal Meningitis
RandomizedParallel-groupOpen-labelTreatment
Summary
Cryptococcal meningitis (CM) is one of the leading opportunistic infections and one of the most common causes of death in AIDS patients. Amphotericin B (AmB) is the corner stone in CM treatment. The effect of AmB was dose-dependent. Recent retrospective study indicated that longer duration rather than higher dose of AmB is necessary to reduce the mortality of CM. We aimed to explore the efficacy and safety of small dose but longer duration of AmB for the treatment of HIV-associated CM.
Timeline
- Start
- 2020-01-02
- Primary completion
- 2022-03-30
- Completion
- 2022-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amphotericin B | Unknown | 0.5 mg/kg | Intravenous |
| Subject | Amphotericin B | Unknown | 0.7 mg/kg | Intravenous |
| Subject | Flucytosine | Small molecule | 100 mg/kg | Oral |